



# CAR T CELL THERAPY

#cartincanada

named science advance of the year in 2018 by ASCO



how will CAR T-cell therapy fit into current treatment paradigms in canada?  
...we were sort of hoping you could help us with the answer

## CAR-T - HOW DOES IT WORK?

CAR T-cell therapy leverages the natural ability of the human body's immune system to detect and destroy cancer cells. CAR T-cell therapy involves genetically transferring the CAR gene directly into a patient's own T- cells, which have been collected by leukapheresis. the CAR equips the T-cells to recognize and destroy cancer cells when infused back into the patient.



## THE HUMAN BODY...AMAZING OR WHAT!



### CLINICAL TRIALS

have demonstrated high efficacy for relapsed & refractory B-cell acute lymphoblastic leukaemia & lasting remissions have been reported.

have demonstrated encouraging results for relapsed & refractory chronic lymphocytic leukaemia & non-Hodgkin lymphoma, with durable remissions reported.

## WHICH PATIENTS ARE CONSIDERED GOOD CANDIDATES FOR CAR T-CELL THERAPY?

### GOOD QUESTION!

patient selection criteria STILL isn't clear & there still hasn't been any public disclosure on what patient eligibility might look like. without that information, managing patient expectations will be difficult. we need appropriate policies to ensure the right patients are getting access.



## LET'S ENSURE PATIENTS DON'T FALL THROUGH THE CRACKS



### YOU CAN'T PUT A PRICE TAG ON REMISSION

but if we had to novartis' kymriah [475.000\$usd] & gilead's yescarta [373.000\$usd]

**\$800.000** is the estimated cost of sending a patient outside of canada to receive car t-cell therapy

### LET'S GET CAR-T REIMBURSED ALREADY!

## LET'S TALK VALUE

the future of therapeutic innovation & increased pressure on health budgets will require alternative, more flexible reimbursement models that allow alignment of medicine prices with the value they deliver in treating diseases.



## AN ADAPTIVE PARTNER ECOSYSTEM IS ESSENTIAL TO THE SUSTAINABILITY & GROWTH OF OUR HEALTHCARE SYSTEM!



### ACCESS TO INNOVATION + SUSTAINABILITY

risk sharing agreements allow patients access to innovative medicines in a context of uncertainty about the clinical benefit & cost effectiveness of innovative medicines & reduces the risk of unnecessary expenses by payors.

### INNOVATION + COLLABORATION = CHANGE

